SRPT Q3 2022 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$230M+21.6% YoY

Gross Profit

$190M82.6% margin

Operating Income

-$131M-57.0% margin

Net Income

-$258M-111.9% margin

EPS (Diluted)

$-2.94

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$74M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$3.2B

Total Liabilities

$2.7B

Stockholders' Equity

$431M

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$230M	$189M	+21.6%
Gross Profit	$190M	$166M	+14.7%
Operating Income	-$131M	-$34M	-281.2%
Net Income	-$258M	-$48M	-435.3%